MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway

Although 5-year survival rate of non-metastatic colorectal cancer (CRC) is high, about 10% of patients in stage I and II still develop into metastatic CRC and eventually die after resection. Currently, there is no effective biomarker for predicting the prognosis of non-metastatic CRC in clinical pra...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Chunxian, Cui, Fengyun, Li, Jiali, Wang, Diyi, Wei, Yingze, Wu, Ying, Wang, Jiping, Zhu, Hongguang, Wang, Shuyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564786/
https://www.ncbi.nlm.nih.gov/pubmed/28548936
http://dx.doi.org/10.18632/oncotarget.17743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564786/
https://www.ncbi.nlm.nih.gov/pubmed/28548936
http://dx.doi.org/10.18632/oncotarget.17743

Ejemplares similares